A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Budapest

Budapest

Tatabánya

Nyíregyháza

Szentes

Szekszárd

Székesfehérvár

Barcelona

Vic

Sopron

Körmend

New York

Garden City

Kingston

Binghamton

Henningsdorf

Bala-Cynwyd

Philadelphia

Hagenow

West Reading

Virginia Beach

Winston-Salem

Raleigh

Madrid

Madrid

Charlotte

Hickory

Coslada

Getafe Madrid

Greer

Simpsonville

Alpharetta

Roswell

Tallahassee

Pembroke Pines

Pembroke Pines

Miami

Aventura

Lauderdale Lakes

West Palm Beach

Wellington

St. Petersburg

Clearwater

Clearwater

Sarasota

Homewood

Huntsville

Mobile

Gran Canaria

Louisville

Madisonville

Columbus

Cleveland

Lyndhurst

Wadsworth

Cincinnati

Fort Wayne

Jeffersonville

West Des Moines

Koblenz

Bad Ems

Billings

Melrose Park

Frankfurt

Overland Park

Neunkirchen

Wichita

Omaha

Lincoln

Shreveport

Little Rock

Bethany

Edmond

Dallas

Arlington

Houston

Corpus Christi

Denver

Salt Lake City

Chandler

Tucson

Tucson

Albuquerque

Albuquerque

Las Vegas

Los Angeles

Torrance

Buena Park

Tarzana

La Mesa

San Diego

San Bernardino

Newport Beach

Fresno

Atherton

Mountlake Terrace

Seattle

Spokane

New Britain

Waterbury

Springfield

Watertown

Lawrenceville

Warwick

Vancouver

Victoria

Winnipeg

Bathurst

Saint John

Barrie

Brampton

Brantford

Kitchener

North Bay

Thunder Bay

Toronto

Toronto

Granby

Sherbrooke

Olomouc

Ostrava

Prague

Prague

Prague

Aalborg

Aarhus N

Frederiksberg

Holstebro

Helsinki

Oulu

Tampere

Eisleben Lutherstadt

Halle

Hettstedt

Leipzig

Neustadt in Sachsen

Radebeul

Sangerhausen

Bergen

Hamar

Tønsberg

Martin

Trenčín

Žilina

Gothenburg

Huddinge

Jönköping

Karlshamn

Malmo

Stockholm

Stockholm